Webinars
Sign up for one of our free Webinars to learn about basic and advanced science topics, get tips and techniques for your lab, or find out more about new technologies and products. Webinars cover educational topics in life science research, drug discovery, clinical research, applied sciences, clinical and molecular diagnostics, and more. Live presentations include the opportunity to ask questions via chat. Don't worry if you missed a presentation date—past Webinars are available for on-demand viewing.
Upcoming Webinars
Enabling High-Throughput Screening and Characterization of Targeted Protein Degraders with HiBiT Technology
Targeted protein degradation is emerging as a promising new modality in drug discovery. Degraders are highly attractive as therapeutics and offer unique advantages in achieving high degradation potency through catalytic, event-driven pharmacology without posing strict requirements on the target binding site or affinity. However, significant challenges persist to efficiently screen for degraders and characterize their cellular mechanisms and dynamic degradation responses. Join our featured speakers from Promega and Evotec to learn how high-throughput targeted protein degradation platforms can be developed using HiBiT technology and the assessment of cellular protein-protein or protein-small molecule interactions by NanoBRET technology, including binary engagement, ternary complex formation, and ubiquitination.
Presenters:
Dr. Kristin Riching, Sr Research Scientist and Group Leader, Promega
Dr. Pierrick Rochard, Group Leader, High Throughput Biology and Screening, Evotec
Dr. Mélissanne de Wispelaere, Molecular Virologist and Group Leader, Evotec
Date:
Tuesday, September 24, 2024 - 9am CDT / 10am EDT / 3pm London / 4pm Amsterdam-Paris
Wednesday, September 25, 2024 - 12pm Singapore / 2pm Sydney / 1pm Seoul / 9:30am New Delhi
Register Here:
Improving FFPE DNA Purification Workflows with Chemical Catalysts
Formalin-fixed paraffin-embedded (FFPE) tissues are an important sample type. Before DNA is purified from FFPE, formalin crosslinks must be reversed using long incubations at high temperatures. This decrosslinking step can compromise nucleic acid quality and pose challenges for laboratory workflows. This webinar will share novel chemical methods that catalyze the reversal of formalin-induced DNA-DNA/protein crosslinks.
Presenters:
Dr. Kevin Mayer, Senior Research Scientist, Promega Corporation
Date:
Wednesday, October 2, 2024 - 9am CDT / 10am EDT / 3pm London / 4pm Amsterdam-Paris
Thursday, October 3, 2024 - 12pm Singapore / 2pm Sydney / 1pm Seoul / 9:30am New Delhi
Register Here:
Wednesday, Oct 2 Thursday, Oct 3Illuminating New Frontiers-Cracking the Undruggable Code
We invite you on a groundbreaking journey across the evolving landscape of drug discovery. This three-day virtual event unites trailblazers in science and industry to explore how innovative approaches are reshaping our ability to tackle 'undruggable' targets. From the complexities of the RAS pathway and the intricacies of protein-protein interactions to the pioneering fields of targeted protein degradation/induced proximity and RNA targeting, each day illuminates a different frontier of therapeutic potential.
We stand at the cusp of a new era, where challenges become opportunities for breakthroughs that extend beyond conventional boundaries. This event is a testament to the power of collaboration and innovation in unveiling new therapeutic strategies, offering hope for untreatable conditions. Join us as we navigate the cutting-edge of science, inspiring a future where every target is within our reach, and no patient is left without options.
Day 1 - Rethinking Undruggable Targets: New Insights into RAS and Protein Interactions
In the realm of drug discovery, certain targets have long been deemed "undruggable" due to their complex nature and the technical challenges associated with modulating them therapeutically. Among these, the RAS pathway stands out as an important element in cell signaling implicated in numerous cancers and diseases. Historically deemed undruggable due to its complex biochemistry and lack of suitable binding sites, RAS has recently witnessed a paradigm shift. Recent innovations in molecular biology—coupled with breakthroughs in drug design and technology—have challenged the notion that the RAS pathway is undruggable, leading to the development and market approval of RAS-targeting therapeutics. Similarly, protein-protein interactions (PPIs)—key elements of RAS signaling—represent untapped therapeutic potential, offering avenues to intervene in disease processes in ways previously deemed infeasible. In this session, we will explore the latest research targeting the RAS/MEK/ERK signaling pathway and learn about novel approaches being developed to manipulate and measure PPIs within RAS and other signaling networks.
Presenters:
Arvin Dar, PhD, Sloan Kettering Institute, MSKCC
HyunHee Cho, Novartis BioMedical Research
Tommy Turbyville, Ph.D, National Cancer Institute-RAS Initiative
Marie Schwinn, PhD, Promega
Date:
Tuesday, October 22 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Day 2 - Next-Generation Therapeutics: The Power of Induced Proximity and Targeted Protein Degradation
Efforts to develop treatments for previously “undruggable” targets have launched a new phase in drug discovery, highlighted by the rise of next-generation therapeutics. Induced proximity, a strategy manipulating molecular interactions for desired outcomes, and targeted protein degradation, leveraging the cell's machinery to degrade pathogenic proteins, are forging new treatment paradigms and redefining our ability to modulate previously intractable molecular targets. In this session we will hear from leading experts as they present the latest research in this fast-moving field and learn how these cutting-edge strategies are transforming how we are tackling diseases once considered beyond reach.
Presenters:
Fleur Ferguson, PhD, University of California, San Diego
Georg Winter, PhD, Center for Molecular Medicine of the Austrian Academy of Sciences
Kristin M. Riching, PhD, Promega
Zoran Rankovic, PhD, The Institute of Cancer Research
Date:
Wednesday, October 23 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Day 3 - Unlocking the Potential of RNA: New Paths for Targeting RNA
This session delves into the innovative realm of RNA as a key therapeutic target in modern drug discovery. Long considered a challenging prospect due to its dynamic nature and critical role in gene regulation, RNA offers unique opportunities for intervention. We will explore cutting-edge advancements in directly targeting RNA molecules and RNA-protein interactions, which are opening new avenues in treatment strategies. Discover how novel RNA-targeting techniques are transforming our ability to influence genetic and cellular functions, presenting potential cures for previously untreatable conditions.
Presenters:
Amanda Garner, PhD, University of Michigan
Matt Disney, PhD, Scripps Institute
John S. Schneekloth, Jr. (Jay), PhD, National Cancer Institute, Frederick, MD
Brad Swanson, Ph.D, Promega Corporation
Date:
Thursday, October 24 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Register Here:
Full 3-day Event Day 1 only Day 2 only Day 3 only
